China Resources Pharma completed a $1.8 billion Hong Kong IPO and dropped slightly in its first day of trading; WuXi PharmaTech participated in the $116 million Series B funding of Unity Biotech, a San Francisco company targeting senescent cells; Guangdong Kanghua Healthcare will stage a $154 million IPO in Hong Kong next month; China’s Innovative Medical Management plans to invest $30 million in Pluristem, an Israeli regenerative medicine company; Athenex Pharma will market five of Beijing Sciecure’s injectible oncology products in the US; the CFDA said 83% of the requests involved in the clinical data Self-Examination validation were voluntarily withdrawn; Beijing’s Yisheng Biopharma was granted US Orphan Drug Designation for its hepatocellular cancer immunotherapy; and Biohit Oyj, a Finnish medical diagnostics company, was granted a China production license for its GastroPanel® products.
